by David Eyre | Sep 6, 2022 | UK
In the case of Neurim and Flynn v Mylan [2022] EWCA Civ 699 The Court of Appeal has issued a decision finding that the plausibility of a therapeutic effect can be demonstrated using subjective data obtained by questioning the users of a pharmaceutical product....
by Juliette Boynton | Aug 12, 2022 | EPO
In an opposition against a patent granted in the name of Canon Kabushiki Kaisha, André Nickel as opponent indicated that the opposition was filed against claims 8 and 9, and not the patent “as a whole”. Argumentation in support of the opposition was provided, this...
by Sean Hutchinson | Aug 9, 2022 | US & International
Background Under the Civil Code of China, “likenesses” of individuals are protected as personality rights. Specifically, no party is entitled to use an image of a person without that person’s consent. This is known as the “right to likeness” and is detailed in Article...
by Sean Hughes | Aug 5, 2022 | Trademarks
Background Despite difficulties in practice, Article 3 of Directive (EU) 2015/2436 provides that colours can be registered as trade marks. A colour must, however, constitute a ‘sign’ and it is this context which has made the process of registering a colour as a trade...
by Sean Hutchinson | Aug 1, 2022 | EPO
Background There has recently been an extensive debate surrounding the legal basis for the EPO’s practice of requiring an Applicant of a European patent application to amend the description of the application to bring this into conformity with the allowed claims. This...
by George Schlich | Jul 19, 2022 | EPO
A copy of our Amicus Curiae brief is reproduced below and can be downloaded here: Schlich Amicus Curiae – 18 July 2022. Executive Summary These combined referrals from Board 3.3.04, G1/22 and G2/22, are both headed “Entitlement to priority” [1]. Decision T844/18...
Recent Comments